Cartherics Expands Catalent Partnership and Secures Japanese Patent for Off-the-Shelf CAR-NK Cell Therapies
Key Insights
Cartherics (search) has signed an amended commercial license agreement with Catalent, enabling use of a cGMP-compliant iPSC line for manufacturing and commercializing CAR-NK cell therapies targeting cancer and endometriosis (search).
The US FDA has approved the licensed iPSC line as the starting cell for generating Cartherics (search)' lead product CTH-401, which targets the tumor antigen TAG-72 (search).
The Japanese Patent Office has granted Cartherics (search) a second patent protecting gene-edited iPSCs incorporating its chimeric antigen receptor constructs, strengthening its global IP portfolio.
Cartherics (search), an Australia-based biotechnology company developing off-the-shelf immune cell therapies for high-impact women's diseases, has announced two significant milestones: an enhanced partnership with Catalent, Inc. and the issuance of a second Japanese patent covering its cell therapy platform. These developments strengthen the company's position as it advances toward clinical trials for its lead CAR-NK cell product, CTH-401.
Expanded Catalent Partnership and FDA Approval
Cartherics (search) and Catalent have signed an amended commercial license agreement enabling the use of a Catalent cGMP-compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics' iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. The agreement supports Cartherics' mission to develop immune cell therapy products for the treatment of cancer and endometriosis (search).
Under the terms of the agreement, Cartherics (search) is granted rights to develop and commercialize multiple product candidates derived from a Catalent off-the-shelf cGMP iPSC line, including its lead CAR-NK cell product, CTH-401. The licensed iPSC line is part of a broader portfolio of fully characterized, donor-consented, clinical-grade iPSC lines generated under GMP conditions, supported by validated workflows for reprogramming, expansion, gene editing, differentiation, and quality control.
With Catalent's support, Cartherics (search) has already obtained approval from the US Food and Drug Administration (FDA) for use of the licensed iPSC line as the starting cell for generation of CTH-401. The two companies have also demonstrated full compatibility between CTH-401 and Catalent's iPSC-NK manufacturing platform.
The agreement enhances Cartherics (search)' manufacturing capabilities by providing a robust framework for collaboration and incentives for utilizing Catalent as its contract manufacturing organization for late-stage clinical trials and commercial supply. Importantly, Cartherics retains the ability to manufacture clinical trial material and retains the right to participate in downstream manufacturing as the partnership evolves.
Japanese Patent Strengthens Global IP Strategy
In a parallel development, the Japanese Patent Office has issued a new patent for Cartherics (search)' off-the-shelf immune cell therapies. This grant, the second in Japan from this patent family, extends protection for key features of induced pluripotent stem cells that have been gene-edited to incorporate the company's chimeric antigen receptor constructs for cancer and, potentially, endometriosis (search).
The Japanese patent is viewed by the company as an important milestone in its global IP strategy. Japan represents a major market for regenerative medicine and advanced cell therapies, offering significant commercial and partnering opportunities.
Dr. Ian Nisbet, Chief Executive of Cartherics (search), stated: "Cartherics has invested heavily in generating a cell therapy platform, particularly directed towards iPSC-derived CAR iNK natural killer cells, that is covered by an extensive portfolio of patents. Issuance of this Japanese patent is a significant addition to the Company's portfolio."
Clinical Development Pathway
Cartherics (search) is focused on high-impact women's diseases with lead programs in ovarian cancer (search) and endometriosis (search). Its allogeneic cell platform is based on iPSCs derived from donated cord blood that can be differentiated into NK cells, T cells, and other immune cells.
The company's lead product, CTH-401, is a CAR iNK cell therapy targeting the tumor antigen TAG-72 (search). Cartherics (search) has initiated manufacturing of clinical trial material in upgraded clean rooms and plans to file an Investigational New Drug application in late 2026, with first-in-human trials in ovarian cancer (search) to follow.